News

We asked the Managed Healthcare Executive editorial advisory board, if you could change one thing about the healthcare industry what would it be? Here’s what they said.

The FDA accelerated approval for Darzalex injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy or who are double-refractory to a PI and an immunomodulatory agent.

Read about what the Democratic candidates for president would do to change the healthcare system in the U.S.

FDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have Hemophilia A.

FDA approved Yondelis (trabectedin), by Janssen Biotech for the treatment of patients with unresectable or metastatic liposarcoma (LPS) or leiomyosarcoma (LMS) who received a prior anthracycline-containing regimen.

FDA recently approved Harvoni for expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus infection – as well as in hepatitis C patients co-infected with HIV.

Sarilumab, an investigational, human antibody against the IL-6 receptor, is highly effective in the difficult-to-treat TNF-IR population in rheumatoid arthritis (RA), according to data presented during the American College of Rheumatology (ACR) Annual Meeting in San Francisco, California.

Managed Healthcare Executive has sorted through the platforms of the Republicans running for president to tell you where they stand on healthcare issues.

A new Urban Institute study looks at the availability of antidepressants in marketplace insurance plans.

A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis negatively impacts patients.

The Food and Drug Administration last week approved Genvoya, marketed by Gilead Sciences, to treat HIV-1 infection.

CMS recently released 2016 Star Rating data, and the news is not good for many Medicare plans, particularly for standalone Part D prescription drug plans.

Payers are in the strongest-position to activate the transition to value-based management models, but they must improve collaboration with providers.

The risk corridor program was intended to subsidize losses for care for expensive new patients brought in by the ACA, but it's not matching up to reality.

FDA has approved talimogene laherparepvec (Imlygic, Amgen) for the treatment of unresectable melanoma lesions.

An important question is whether improvements in technology can make better control accessible to patients who are not currently good candidates for insulin pumps.

Today’s consumers have high expectations when making a retail purchase. These same demands apply when purchasing health insurance and getting medical care.

Deaths from drug overdoses are the leading cause of injury death in the United States, ahead of deaths linked to motor vehicles and firearms, according to the new 2015 National Drug Threat Assessment (NDTA), released by the Drug Enforcement Administration.

Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA, will speak about the future of drug development in pulmonary fibrosis during the PFF Summit 2015: From Bench to Bedside conference, November 12-14 in Washington D.C.

A survey of 2,398 physician leaders across the country indicates how physicians are changing their views on value-based care. View the survey findings.

After Valeant and Express Scripts cut ties with mail order specialty pharmacy Philidor Rx Services, the company said it would be closing.

Advancements in IV robotics are mitigating the risks of human error in the compounding process. The misconceptions of IV robotics are many, but there are also many real world examples of how hospitals and health systems are improving processes by implementing technology to support in-house sterile compounding.

Following the ICD-10 transition, real interplay between all stakeholders begins with the patient being the true focus.

While Gilead works on a “cure,” here are four things managed care executives need to know about the current state of HIV treatment

Today’s value-focused economy was a primary discussion point at a recent roundtable of health plan CEOs. The discussion led to five essential attributes that organizations must embrace to thrive.

FDA approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) and the stand-alone monotherapy Seebri Neohaler (glycopyrrolate) – which is one component of Utibron Neohaler -- for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

As healthcare consumerism gains momentum, health plans need to change their offerings to keep up with consumer demands.

While many believe biosimilars have great potential, challenges remain.

These services can detect diseases earlier and prevent them altogether, but rates are lagging behind where they should be.

How advanced use of data and analytics can solve your biggest Star Ratings challenges